CA2092408A1 - Radioprotection par antagonistes du calcium - Google Patents

Radioprotection par antagonistes du calcium

Info

Publication number
CA2092408A1
CA2092408A1 CA002092408A CA2092408A CA2092408A1 CA 2092408 A1 CA2092408 A1 CA 2092408A1 CA 002092408 A CA002092408 A CA 002092408A CA 2092408 A CA2092408 A CA 2092408A CA 2092408 A1 CA2092408 A1 CA 2092408A1
Authority
CA
Canada
Prior art keywords
calcium
calcium antagonist
diltiazem
combination
nifedipine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002092408A
Other languages
English (en)
Inventor
Georges Floersheim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP3509123A priority Critical patent/JPH06501917A/ja
Priority to CA002092408A priority patent/CA2092408A1/fr
Priority to PCT/EP1991/001410 priority patent/WO1993002670A1/fr
Priority to EP91913806A priority patent/EP0550446A1/fr
Publication of CA2092408A1 publication Critical patent/CA2092408A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CA002092408A 1991-07-27 1991-07-27 Radioprotection par antagonistes du calcium Abandoned CA2092408A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP3509123A JPH06501917A (ja) 1991-07-27 1991-07-27 カルシウム拮抗剤による放射線保護
CA002092408A CA2092408A1 (fr) 1991-07-27 1991-07-27 Radioprotection par antagonistes du calcium
PCT/EP1991/001410 WO1993002670A1 (fr) 1991-07-27 1991-07-27 Protection contre les rayonnements a l'aide d'antagonistes du calcium
EP91913806A EP0550446A1 (fr) 1991-07-27 1991-07-27 Protection contre les rayonnements a l'aide d'antagonistes du calcium

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002092408A CA2092408A1 (fr) 1991-07-27 1991-07-27 Radioprotection par antagonistes du calcium
PCT/EP1991/001410 WO1993002670A1 (fr) 1991-07-27 1991-07-27 Protection contre les rayonnements a l'aide d'antagonistes du calcium

Publications (1)

Publication Number Publication Date
CA2092408A1 true CA2092408A1 (fr) 1993-01-28

Family

ID=25676020

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002092408A Abandoned CA2092408A1 (fr) 1991-07-27 1991-07-27 Radioprotection par antagonistes du calcium

Country Status (4)

Country Link
EP (1) EP0550446A1 (fr)
JP (1) JPH06501917A (fr)
CA (1) CA2092408A1 (fr)
WO (1) WO1993002670A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101831779B1 (ko) * 2016-10-14 2018-02-23 한국원자력의학원 니솔디핀을 유효성분으로 함유하는 방사선 보호제용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4435409A (en) * 1981-12-10 1984-03-06 Usv Pharmaceutical Corporation Method of stimulating production of IgM antibodies
DE3577184D1 (de) * 1984-01-13 1990-05-23 Yamanouchi Pharma Co Ltd Arzneimittel fuer die behandlung und verhuetung von leberschaedigungen.

Also Published As

Publication number Publication date
EP0550446A1 (fr) 1993-07-14
JPH06501917A (ja) 1994-03-03
WO1993002670A1 (fr) 1993-02-18

Similar Documents

Publication Publication Date Title
KR930008954B1 (ko) 약용 서방 기제
Cascinu et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial.
AU663303B2 (en) Compositions containing sumatriptan
Maini et al. 153 Sm-EDTMP for bone pain palliation in skeletal metastases
Atkins et al. Tin-117m (4+)-DTPA for palliation of pain from osseous metastases: a pilot study
US6391911B1 (en) Coadministration of lucanthone and radiation for treatment of cancer
Shani et al. A model for prediction of chemotherapy response to 5-fluorouracil based on the differential distribution of 5-[18F] fluorouracil in sensitive versus resistant lymphocytic leukemia in mice
CZ287558B6 (en) Pharmaceutical preparation
Floersheim Radioprotective effects of calcium antagonists used alone or with other types of radioprotectors
AU717382B2 (en) Use of benzimidazoles for the manufacture of a medicament for the treatment of leukemia
CN117159753A (zh) 放射性标记的伊文思蓝衍生物药物的制备方法及用途
Akine et al. Neutron-capture therapy of murine ascites tumor with gadolinium-containing microcapsules
US5824346A (en) Combination therapy for advanced cancer
CA2092408A1 (fr) Radioprotection par antagonistes du calcium
US20230210779A1 (en) Controlled-release tablet of ibuprofen and method for preparing same
Liebmann et al. Protection from lethal irradiation by the combination of stem cell factor and tempol
Grebenyuk et al. Modern condition and prospects for the development of medicines towards prevention and early treatment of radiation damage
Car et al. A double-blind multicentre comparison of diclofenac sodium and naproxen in osteoarthrosis of the hip
Menard et al. Radioprotection against cataract formation by WR-77913 in gamma-irradiated rats
George et al. Cytotoxic effect of chlorpromazine and its interaction with radiation on a mouse fibrosarcoma
HU180443B (en) Process for preparing a pharmaceutical preparation with synergetic action against radiation
Buzdar et al. Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer.
CN111569078A (zh) Sirt1抑制剂在vegfr抑制剂与免疫检查点抑制剂联用引起的副作用上的应用
Pageau et al. Systemic Protection against Radiation: I. Effect of an Elemental Diet on Hematopoietic and Immunologic Systems in the Rat
CA1200499A (fr) Composes synergetiques de nalbuphine et d'un analgesique non narcotique

Legal Events

Date Code Title Description
FZDE Discontinued